Why the study?
Roux-en-Y gastric bypass is effective for metabolic disorder, but whether ghrelin contributes to the resulting weight reduction and glycemic and lipid control remains unclear.
Does lower ghrelin level impact the metabolic benefits (weight reduction, glycemic and lipid control) induced by Roux-en-Y gastric bypass in mice?
Does lower ghrelin level impact the metabolic benefits (weight reduction, glycemic and lipid control) induced by Roux-en-Y gastric bypass in mice?
Lower ghrelin levels do not appear to mediate the metabolic benefits of Roux-en-Y gastric bypass in a mouse model.
RYGB-induced ghrelin changes in obese mice are hypothesis-generating; leaves open causal contribution to human weight and glycemic outcomes.
Objective: Roux-en-Y gastric bypass is an effective intervention for metabolic disorder. We aim to elucidate whether ghrelin contributes to weight reduction, and glycemic and lipid control after Roux-en-Y gastric bypass (RYGB). Design: mice were fed high fat diet for 12 weeks before surgery, and continued to be on the same diet for 3 weeks after surgery. Body weight, food intake, glycemic and lipid metabolism were analyzed before and after surgery. Results: Gastric and circulating ghrelin was significantly increased in mice with RYGB surgery. Hypoghrelinemia elicited by deletion of TSC1 to activate mTOR signaling in gastric X/A like cells demonstrated no effect on weight reduction, glycemic and lipid control induced by Roux-en-Y gastric bypass surgery. Conclusion: Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: